- Home
- POCI vs NRSN Comparison
POCI vs NRSN Comparison
Compare POCI & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POCI
- NRSN
- Stock Information
- Founded
- POCI 1982
- NRSN 2017
- Country
- POCI United States
- NRSN Israel
- Employees
- POCI N/A
- NRSN N/A
- Industry
- POCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- POCI Health Care
- NRSN Health Care
- Exchange
- POCI Nasdaq
- NRSN Nasdaq
- Market Cap
- POCI 31.0M
- NRSN 26.0M
- IPO Year
- POCI N/A
- NRSN 2021
- Fundamental
- Price
- POCI $3.95
- NRSN $1.03
- Analyst Decision
- POCI
- NRSN Hold
- Analyst Count
- POCI 0
- NRSN 1
- Target Price
- POCI N/A
- NRSN N/A
- AVG Volume (30 Days)
- POCI 11.7K
- NRSN 135.5K
- Earning Date
- POCI 05-14-2025
- NRSN 04-07-2025
- Dividend Yield
- POCI N/A
- NRSN N/A
- EPS Growth
- POCI N/A
- NRSN N/A
- EPS
- POCI N/A
- NRSN N/A
- Revenue
- POCI $18,682,766.00
- NRSN N/A
- Revenue This Year
- POCI N/A
- NRSN N/A
- Revenue Next Year
- POCI N/A
- NRSN N/A
- P/E Ratio
- POCI N/A
- NRSN N/A
- Revenue Growth
- POCI N/A
- NRSN N/A
- 52 Week Low
- POCI $3.47
- NRSN $0.51
- 52 Week High
- POCI $6.90
- NRSN $1.73
- Technical
- Relative Strength Index (RSI)
- POCI 40.65
- NRSN 49.96
- Support Level
- POCI $3.90
- NRSN $1.00
- Resistance Level
- POCI $4.28
- NRSN $1.04
- Average True Range (ATR)
- POCI 0.28
- NRSN 0.09
- MACD
- POCI -0.00
- NRSN 0.01
- Stochastic Oscillator
- POCI 19.57
- NRSN 76.25
About POCI Precision Optics Corporation Inc.
Precision Optics Corp Inc is engaged in designing, developing, and manufacturing advanced optical instruments. It manufactures medical products such as endoscopes and endocouplers which incorporate various optical technologies for use in a variety of minimally invasive surgical and diagnostic procedures. The company also produces endoscopes for various applications as well as designs and manufactures custom optical medical devices to satisfy customers' specific requirements. In addition, the company manufactures and sells components and assemblies specially designed for industrial and military use. The company earns the majority of its revenue from the United States.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.